ID

DB08972||

名称

Flumequine

描述

Flumequine is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class used to treat bacterial infections.

cas号

42835-25-6

唯一标识码

UVG8VSP2SJ

状态

solid

组

withdrawn,

指示

药效学

作用机制

毒性

代谢

吸收

半衰期

分类

description:This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
direct-parent:Quinoline carboxylic acids
kingdom:Organic compounds
superclass:Organoheterocyclic compounds
class:Quinolines and derivatives
subclass:Quinoline carboxylic acids
alternative-parent:Aryl fluorides
alternative-parent:Azacyclic compounds
alternative-parent:Benzenoids
alternative-parent:Carboxylic acids
alternative-parent:Fluoroquinolones
alternative-parent:Haloquinolines
alternative-parent:Heteroaromatic compounds
alternative-parent:Hydrocarbon derivatives
alternative-parent:Hydroquinolines
alternative-parent:Hydroquinolones
alternative-parent:Monocarboxylic acids and derivatives
alternative-parent:Organic oxides
alternative-parent:Organofluorides
alternative-parent:Organonitrogen compounds
alternative-parent:Organooxygen compounds
alternative-parent:Organopnictogen compounds
alternative-parent:Pyridinecarboxylic acids
alternative-parent:Vinylogous amides
substituent:Aromatic heteropolycyclic compound
substituent:Aryl fluoride
substituent:Aryl halide
substituent:Azacycle
substituent:Benzenoid
substituent:Carboxylic acid
substituent:Carboxylic acid derivative
substituent:Dihydroquinoline
substituent:Dihydroquinolone
substituent:Fluoroquinolone
substituent:Haloquinoline
substituent:Heteroaromatic compound
substituent:Hydrocarbon derivative
substituent:Monocarboxylic acid or derivatives
substituent:Organic nitrogen compound
substituent:Organic oxide
substituent:Organic oxygen compound
substituent:Organofluoride
substituent:Organohalogen compound
substituent:Organonitrogen compound
substituent:Organooxygen compound
substituent:Organopnictogen compound
substituent:Pyridine
substituent:Pyridine carboxylic acid
substituent:Pyridine carboxylic acid or derivatives
substituent:Quinoline-3-carboxylic acid
substituent:Vinylogous amide

消除途径

种类

Anti-Bacterial Agents
D000900
Anti-Infective Agents
D000890
Anti-Infective Agents, Urinary
D000892
Antibacterials for Systemic Use

Antiinfectives for Systemic Use

Antineoplastic Agents
D000970
Cytochrome P-450 CYP1A2 Inhibitors
D065609
Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)

Cytochrome P-450 Enzyme Inhibitors
D065607
Enzyme Inhibitors
D004791
Fluoroquinolones
D024841
Heterocyclic Compounds, Fused-Ring
D000072471
Potential QTc-Prolonging Agents

QTc Prolonging Agents

Quinolines
D011804
Quinolones
D015363
Renal Agents
D012076
Topoisomerase II Inhibitors
D059005
Topoisomerase Inhibitors
D059003

盐类

蛋白质结合

清除

同义词

language:english; code:inn; name;Flumequine

国际品牌

配送量

产品

混合物

包装者

生产者

价格

受影响的生物体

剂量

form:Tablet
route:
strength:400 MG

atc代码

Other quinolones
QUINOLONE ANTIBACTERIALS
ANTIBACTERIALS FOR SYSTEMIC USE
ANTIINFECTIVES FOR SYSTEMIC USE

fda标签

化学品安全技术说明书

专利

食物相互作用

药物相互作用

DB00012
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Flumequine.
DB00016
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Flumequine.
DB08894
The risk or severity of Thrombosis can be increased when Peginesatide is combined with Flumequine.
DB09107
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Flumequine.
DB00900
Didanosine can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01032
Probenecid may decrease the excretion rate of Flumequine which could result in a higher serum level.
DB00881
Quinapril can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00258
Calcium acetate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00658
Sevelamer can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00893
Iron Dextran can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01164
Calcium chloride can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01373
Calcium can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06724
Calcium carbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06792
Lanthanum carbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08917
Ferric carboxymaltose can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09146
Iron sucrose can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09147
Ferric pyrophosphate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09517
Sodium ferric gluconate complex can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11093
Calcium citrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11126
Calcium gluconate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11171
Ferric sulfate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13949
Ferric cation can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13995
Ferric pyrophosphate citrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14520
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14579
Lanthanum III cation can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14684
Calcium polycarbophil can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14695
Ferric oxyhydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00364
Sucralfate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00315
The metabolism of Zolmitriptan can be decreased when combined with Flumequine.
DB00698
The therapeutic efficacy of Flumequine can be decreased when used in combination with Nitrofurantoin.
DB00688
The serum concentration of Mycophenolate mofetil can be decreased when it is combined with Flumequine.
DB01024
The serum concentration of Mycophenolic acid can be decreased when it is combined with Flumequine.
DB09268
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Flumequine.
DB00030
The therapeutic efficacy of Insulin human can be increased when used in combination with Flumequine.
DB00046
The therapeutic efficacy of Insulin lispro can be increased when used in combination with Flumequine.
DB00071
The therapeutic efficacy of Insulin pork can be increased when used in combination with Flumequine.
DB00197
The therapeutic efficacy of Troglitazone can be increased when used in combination with Flumequine.
DB00222
The therapeutic efficacy of Glimepiride can be increased when used in combination with Flumequine.
DB00263
The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Flumequine.
DB00284
The therapeutic efficacy of Acarbose can be increased when used in combination with Flumequine.
DB00331
The therapeutic efficacy of Metformin can be increased when used in combination with Flumequine.
DB00359
The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Flumequine.
DB00412
The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Flumequine.
DB00414
The therapeutic efficacy of Acetohexamide can be increased when used in combination with Flumequine.
DB00491
The therapeutic efficacy of Miglitol can be increased when used in combination with Flumequine.
DB00672
The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Flumequine.
DB00731
The therapeutic efficacy of Nateglinide can be increased when used in combination with Flumequine.
DB00738
The therapeutic efficacy of Pentamidine can be increased when used in combination with Flumequine.
DB00839
The therapeutic efficacy of Tolazamide can be increased when used in combination with Flumequine.
DB00912
The therapeutic efficacy of Repaglinide can be increased when used in combination with Flumequine.
DB00914
The therapeutic efficacy of Phenformin can be increased when used in combination with Flumequine.
DB01015
The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Flumequine.
DB01016
The therapeutic efficacy of Glyburide can be increased when used in combination with Flumequine.
DB01067
The therapeutic efficacy of Glipizide can be increased when used in combination with Flumequine.
DB01120
The therapeutic efficacy of Gliclazide can be increased when used in combination with Flumequine.
DB01124
The therapeutic efficacy of Tolbutamide can be increased when used in combination with Flumequine.
DB01132
The therapeutic efficacy of Pioglitazone can be increased when used in combination with Flumequine.
DB01200
The therapeutic efficacy of Bromocriptine can be increased when used in combination with Flumequine.
DB01251
The therapeutic efficacy of Gliquidone can be increased when used in combination with Flumequine.
DB01252
The therapeutic efficacy of Mitiglinide can be increased when used in combination with Flumequine.
DB01261
The therapeutic efficacy of Sitagliptin can be increased when used in combination with Flumequine.
DB01268
The therapeutic efficacy of Sunitinib can be increased when used in combination with Flumequine.
DB01276
The therapeutic efficacy of Exenatide can be increased when used in combination with Flumequine.
DB01277
The therapeutic efficacy of Mecasermin can be increased when used in combination with Flumequine.
DB01278
The therapeutic efficacy of Pramlintide can be increased when used in combination with Flumequine.
DB01289
The therapeutic efficacy of Glisoxepide can be increased when used in combination with Flumequine.
DB01306
The therapeutic efficacy of Insulin aspart can be increased when used in combination with Flumequine.
DB01309
The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Flumequine.
DB01382
The therapeutic efficacy of Glymidine can be increased when used in combination with Flumequine.
DB01700
The therapeutic efficacy of AICA ribonucleotide can be increased when used in combination with Flumequine.
DB04830
The therapeutic efficacy of Buformin can be increased when used in combination with Flumequine.
DB04876
The therapeutic efficacy of Vildagliptin can be increased when used in combination with Flumequine.
DB04878
The therapeutic efficacy of Voglibose can be increased when used in combination with Flumequine.
DB05115
The therapeutic efficacy of NN344 can be increased when used in combination with Flumequine.
DB05819
The therapeutic efficacy of NBI-6024 can be increased when used in combination with Flumequine.
DB06011
The therapeutic efficacy of AMG-222 can be increased when used in combination with Flumequine.
DB06127
The therapeutic efficacy of Bisegliptin can be increased when used in combination with Flumequine.
DB06203
The therapeutic efficacy of Alogliptin can be increased when used in combination with Flumequine.
DB06292
The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Flumequine.
DB06335
The therapeutic efficacy of Saxagliptin can be increased when used in combination with Flumequine.
DB06655
The therapeutic efficacy of Liraglutide can be increased when used in combination with Flumequine.
DB08382
The therapeutic efficacy of Gosogliptin can be increased when used in combination with Flumequine.
DB08882
The therapeutic efficacy of Linagliptin can be increased when used in combination with Flumequine.
DB08907
The therapeutic efficacy of Canagliflozin can be increased when used in combination with Flumequine.
DB08962
The therapeutic efficacy of Glibornuride can be increased when used in combination with Flumequine.
DB09022
The therapeutic efficacy of Benfluorex can be increased when used in combination with Flumequine.
DB09038
The therapeutic efficacy of Empagliflozin can be increased when used in combination with Flumequine.
DB09043
The therapeutic efficacy of Albiglutide can be increased when used in combination with Flumequine.
DB09045
The therapeutic efficacy of Dulaglutide can be increased when used in combination with Flumequine.
DB09198
The therapeutic efficacy of Lobeglitazone can be increased when used in combination with Flumequine.
DB09199
The therapeutic efficacy of Netoglitazone can be increased when used in combination with Flumequine.
DB09200
The therapeutic efficacy of Rivoglitazone can be increased when used in combination with Flumequine.
DB09201
The therapeutic efficacy of Ciglitazone can be increased when used in combination with Flumequine.
DB09265
The therapeutic efficacy of Lixisenatide can be increased when used in combination with Flumequine.
DB09456
The therapeutic efficacy of Insulin beef can be increased when used in combination with Flumequine.
DB09564
The therapeutic efficacy of Insulin degludec can be increased when used in combination with Flumequine.
DB11567
The therapeutic efficacy of Insulin peglispro can be increased when used in combination with Flumequine.
DB11568
The therapeutic efficacy of Insulin tregopil can be increased when used in combination with Flumequine.
DB11698
The therapeutic efficacy of Ipragliflozin can be increased when used in combination with Flumequine.
DB11723
The therapeutic efficacy of Dutogliptin can be increased when used in combination with Flumequine.
DB11780
The therapeutic efficacy of Allicin can be increased when used in combination with Flumequine.
DB11824
The therapeutic efficacy of Tofogliflozin can be increased when used in combination with Flumequine.
DB11827
The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Flumequine.
DB11898
The therapeutic efficacy of 2,4-thiazolidinedione can be increased when used in combination with Flumequine.
DB11950
The therapeutic efficacy of Teneligliptin can be increased when used in combination with Flumequine.
DB11992
The therapeutic efficacy of Omarigliptin can be increased when used in combination with Flumequine.
DB12268
The therapeutic efficacy of Carmegliptin can be increased when used in combination with Flumequine.
DB12412
The therapeutic efficacy of Gemigliptin can be increased when used in combination with Flumequine.
DB12417
The therapeutic efficacy of Anagliptin can be increased when used in combination with Flumequine.
DB12625
The therapeutic efficacy of Evogliptin can be increased when used in combination with Flumequine.
DB12713
The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Flumequine.
DB12781
The therapeutic efficacy of Balaglitazone can be increased when used in combination with Flumequine.
DB12935
The therapeutic efficacy of Remogliflozin etabonate can be increased when used in combination with Flumequine.
DB13406
The therapeutic efficacy of Carbutamide can be increased when used in combination with Flumequine.
DB13446
The therapeutic efficacy of Guar gum can be increased when used in combination with Flumequine.
DB13675
The therapeutic efficacy of Metahexamide can be increased when used in combination with Flumequine.
DB13928
The therapeutic efficacy of Semaglutide can be increased when used in combination with Flumequine.
DB14027
The therapeutic efficacy of Taspoglutide can be increased when used in combination with Flumequine.
DB14035
The therapeutic efficacy of Englitazone can be increased when used in combination with Flumequine.
DB15171
The therapeutic efficacy of Tirzepatide can be increased when used in combination with Flumequine.
DB15217
The therapeutic efficacy of Gastric inhibitory polypeptide can be increased when used in combination with Flumequine.
DB00047
The therapeutic efficacy of Insulin glargine can be increased when used in combination with Flumequine.
DB01307
The therapeutic efficacy of Insulin detemir can be increased when used in combination with Flumequine.
DB00159
Icosapent may increase the neuroexcitatory activities of Flumequine.
DB00244
Mesalazine may increase the neuroexcitatory activities of Flumequine.
DB00328
Indomethacin may increase the neuroexcitatory activities of Flumequine.
DB00465
Ketorolac may increase the neuroexcitatory activities of Flumequine.
DB00469
Tenoxicam may increase the neuroexcitatory activities of Flumequine.
DB00482
Celecoxib may increase the neuroexcitatory activities of Flumequine.
DB00500
Tolmetin may increase the neuroexcitatory activities of Flumequine.
DB00554
Piroxicam may increase the neuroexcitatory activities of Flumequine.
DB00573
Fenoprofen may increase the neuroexcitatory activities of Flumequine.
DB00580
Valdecoxib may increase the neuroexcitatory activities of Flumequine.
DB00605
Sulindac may increase the neuroexcitatory activities of Flumequine.
DB00712
Flurbiprofen may increase the neuroexcitatory activities of Flumequine.
DB00749
Etodolac may increase the neuroexcitatory activities of Flumequine.
DB00784
Mefenamic acid may increase the neuroexcitatory activities of Flumequine.
DB00795
Sulfasalazine may increase the neuroexcitatory activities of Flumequine.
DB00812
Phenylbutazone may increase the neuroexcitatory activities of Flumequine.
DB00814
Meloxicam may increase the neuroexcitatory activities of Flumequine.
DB00821
Carprofen may increase the neuroexcitatory activities of Flumequine.
DB00861
Diflunisal may increase the neuroexcitatory activities of Flumequine.
DB00936
Salicylic acid may increase the neuroexcitatory activities of Flumequine.
DB00939
Meclofenamic acid may increase the neuroexcitatory activities of Flumequine.
DB00945
Acetylsalicylic acid may increase the neuroexcitatory activities of Flumequine.
DB00991
Oxaprozin may increase the neuroexcitatory activities of Flumequine.
DB01009
Ketoprofen may increase the neuroexcitatory activities of Flumequine.
DB01014
Balsalazide may increase the neuroexcitatory activities of Flumequine.
DB01050
Ibuprofen may increase the neuroexcitatory activities of Flumequine.
DB01250
Olsalazine may increase the neuroexcitatory activities of Flumequine.
DB01283
Lumiracoxib may increase the neuroexcitatory activities of Flumequine.
DB01399
Salsalate may increase the neuroexcitatory activities of Flumequine.
DB01401
Choline magnesium trisalicylate may increase the neuroexcitatory activities of Flumequine.
DB01419
Antrafenine may increase the neuroexcitatory activities of Flumequine.
DB01600
Tiaprofenic acid may increase the neuroexcitatory activities of Flumequine.
DB02224
Taxifolin may increase the neuroexcitatory activities of Flumequine.
DB03585
Oxyphenbutazone may increase the neuroexcitatory activities of Flumequine.
DB04725
Licofelone may increase the neuroexcitatory activities of Flumequine.
DB04743
Nimesulide may increase the neuroexcitatory activities of Flumequine.
DB04812
Benoxaprofen may increase the neuroexcitatory activities of Flumequine.
DB04817
Metamizole may increase the neuroexcitatory activities of Flumequine.
DB04828
Zomepirac may increase the neuroexcitatory activities of Flumequine.
DB05095
Cimicoxib may increase the neuroexcitatory activities of Flumequine.
DB06725
Lornoxicam may increase the neuroexcitatory activities of Flumequine.
DB06736
Aceclofenac may increase the neuroexcitatory activities of Flumequine.
DB06737
Zaltoprofen may increase the neuroexcitatory activities of Flumequine.
DB07402
Azapropazone may increase the neuroexcitatory activities of Flumequine.
DB08439
Parecoxib may increase the neuroexcitatory activities of Flumequine.
DB08797
Salicylamide may increase the neuroexcitatory activities of Flumequine.
DB08940
Kebuzone may increase the neuroexcitatory activities of Flumequine.
DB08942
Isoxicam may increase the neuroexcitatory activities of Flumequine.
DB08951
Indoprofen may increase the neuroexcitatory activities of Flumequine.
DB08955
Ibuproxam may increase the neuroexcitatory activities of Flumequine.
DB08976
Floctafenine may increase the neuroexcitatory activities of Flumequine.
DB08981
Fenbufen may increase the neuroexcitatory activities of Flumequine.
DB08984
Etofenamate may increase the neuroexcitatory activities of Flumequine.
DB08991
Epirizole may increase the neuroexcitatory activities of Flumequine.
DB09084
Benzydamine may increase the neuroexcitatory activities of Flumequine.
DB09213
Dexibuprofen may increase the neuroexcitatory activities of Flumequine.
DB09214
Dexketoprofen may increase the neuroexcitatory activities of Flumequine.
DB09215
Droxicam may increase the neuroexcitatory activities of Flumequine.
DB09216
Tolfenamic acid may increase the neuroexcitatory activities of Flumequine.
DB09217
Firocoxib may increase the neuroexcitatory activities of Flumequine.
DB09218
Clonixin may increase the neuroexcitatory activities of Flumequine.
DB09285
Morniflumate may increase the neuroexcitatory activities of Flumequine.
DB09295
Talniflumate may increase the neuroexcitatory activities of Flumequine.
DB11455
Robenacoxib may increase the neuroexcitatory activities of Flumequine.
DB11466
Tepoxalin may increase the neuroexcitatory activities of Flumequine.
DB11518
Flunixin may increase the neuroexcitatory activities of Flumequine.
DB12399
Polmacoxib may increase the neuroexcitatory activities of Flumequine.
DB12445
Nitroaspirin may increase the neuroexcitatory activities of Flumequine.
DB12545
Indobufen may increase the neuroexcitatory activities of Flumequine.
DB12610
Ebselen may increase the neuroexcitatory activities of Flumequine.
DB13001
Tinoridine may increase the neuroexcitatory activities of Flumequine.
DB13167
Alclofenac may increase the neuroexcitatory activities of Flumequine.
DB13217
Fentiazac may increase the neuroexcitatory activities of Flumequine.
DB13232
Suxibuzone may increase the neuroexcitatory activities of Flumequine.
DB13286
Bumadizone may increase the neuroexcitatory activities of Flumequine.
DB13314
Alminoprofen may increase the neuroexcitatory activities of Flumequine.
DB13371
Difenpiramide may increase the neuroexcitatory activities of Flumequine.
DB13407
Nifenazone may increase the neuroexcitatory activities of Flumequine.
DB13432
Lonazolac may increase the neuroexcitatory activities of Flumequine.
DB13481
Tenidap may increase the neuroexcitatory activities of Flumequine.
DB13524
Propyphenazone may increase the neuroexcitatory activities of Flumequine.
DB13527
Proglumetacin may increase the neuroexcitatory activities of Flumequine.
DB13538
Guacetisal may increase the neuroexcitatory activities of Flumequine.
DB13544
Ethenzamide may increase the neuroexcitatory activities of Flumequine.
DB13612
Carbaspirin calcium may increase the neuroexcitatory activities of Flumequine.
DB13629
Mofebutazone may increase the neuroexcitatory activities of Flumequine.
DB13649
Proquazone may increase the neuroexcitatory activities of Flumequine.
DB13657
Benorilate may increase the neuroexcitatory activities of Flumequine.
DB13722
Pirprofen may increase the neuroexcitatory activities of Flumequine.
DB13783
Acemetacin may increase the neuroexcitatory activities of Flumequine.
DB13860
Imidazole salicylate may increase the neuroexcitatory activities of Flumequine.
DB14059
SC-236 may increase the neuroexcitatory activities of Flumequine.
DB14060
NS-398 may increase the neuroexcitatory activities of Flumequine.
DB14938
Flurbiprofen axetil may increase the neuroexcitatory activities of Flumequine.
DB09212
Loxoprofen may increase the neuroexcitatory activities of Flumequine.
DB09267
Strontium ranelate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00266
The therapeutic efficacy of Dicoumarol can be increased when used in combination with Flumequine.
DB00498
The therapeutic efficacy of Phenindione can be increased when used in combination with Flumequine.
DB00946
The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Flumequine.
DB03410
The therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Flumequine.
DB04665
The therapeutic efficacy of Coumarin can be increased when used in combination with Flumequine.
DB08496
The therapeutic efficacy of (R)-warfarin can be increased when used in combination with Flumequine.
DB08794
The therapeutic efficacy of Ethyl biscoumacetate can be increased when used in combination with Flumequine.
DB13136
The therapeutic efficacy of Fluindione can be increased when used in combination with Flumequine.
DB13275
The therapeutic efficacy of Clorindione can be increased when used in combination with Flumequine.
DB13347
The therapeutic efficacy of Diphenadione can be increased when used in combination with Flumequine.
DB13451
The therapeutic efficacy of Tioclomarol can be increased when used in combination with Flumequine.
DB14055
The therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Flumequine.
DB00682
The therapeutic efficacy of Warfarin can be increased when used in combination with Flumequine.
DB01418
The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Flumequine.
DB00326
Calcium glucoheptonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13231
Calcium lactate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13365
Calcium lactate gluconate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13590
Calcium pangamate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11348
Calcium Phosphate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00180
The risk or severity of tendinopathy can be increased when Flunisolide is combined with Flumequine.
DB00394
The risk or severity of tendinopathy can be increased when Beclomethasone dipropionate is combined with Flumequine.
DB00443
The risk or severity of tendinopathy can be increased when Betamethasone is combined with Flumequine.
DB00588
The risk or severity of tendinopathy can be increased when Fluticasone propionate is combined with Flumequine.
DB00591
The risk or severity of tendinopathy can be increased when Fluocinolone acetonide is combined with Flumequine.
DB00620
The risk or severity of tendinopathy can be increased when Triamcinolone is combined with Flumequine.
DB00635
The risk or severity of tendinopathy can be increased when Prednisone is combined with Flumequine.
DB00687
The risk or severity of tendinopathy can be increased when Fludrocortisone is combined with Flumequine.
DB00741
The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Flumequine.
DB00860
The risk or severity of tendinopathy can be increased when Prednisolone is combined with Flumequine.
DB00959
The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Flumequine.
DB01108
The risk or severity of tendinopathy can be increased when Trilostane is combined with Flumequine.
DB01222
The risk or severity of tendinopathy can be increased when Budesonide is combined with Flumequine.
DB01234
The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Flumequine.
DB01285
The risk or severity of tendinopathy can be increased when Corticotropin is combined with Flumequine.
DB01380
The risk or severity of tendinopathy can be increased when Cortisone acetate is combined with Flumequine.
DB01384
The risk or severity of tendinopathy can be increased when Paramethasone is combined with Flumequine.
DB01410
The risk or severity of tendinopathy can be increased when Ciclesonide is combined with Flumequine.
DB04630
The risk or severity of tendinopathy can be increased when Aldosterone is combined with Flumequine.
DB08906
The risk or severity of tendinopathy can be increased when Fluticasone furoate is combined with Flumequine.
DB08970
The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Flumequine.
DB09091
The risk or severity of tendinopathy can be increased when Tixocortol is combined with Flumequine.
DB09378
The risk or severity of tendinopathy can be increased when Fluprednisolone is combined with Flumequine.
DB09383
The risk or severity of tendinopathy can be increased when Meprednisone is combined with Flumequine.
DB11487
The risk or severity of tendinopathy can be increased when Dexamethasone isonicotinate is combined with Flumequine.
DB11529
The risk or severity of tendinopathy can be increased when Melengestrol is combined with Flumequine.
DB11921
The risk or severity of tendinopathy can be increased when Deflazacort is combined with Flumequine.
DB13003
The risk or severity of tendinopathy can be increased when Cortivazol is combined with Flumequine.
DB13208
The risk or severity of tendinopathy can be increased when Prednylidene is combined with Flumequine.
DB13223
The risk or severity of tendinopathy can be increased when Fluocortin is combined with Flumequine.
DB13491
The risk or severity of tendinopathy can be increased when Fluperolone is combined with Flumequine.
DB13843
The risk or severity of tendinopathy can be increased when Cloprednol is combined with Flumequine.
DB13856
The risk or severity of tendinopathy can be increased when Fluclorolone is combined with Flumequine.
DB13867
The risk or severity of tendinopathy can be increased when Fluticasone is combined with Flumequine.
DB14512
The risk or severity of tendinopathy can be increased when Mometasone furoate is combined with Flumequine.
DB14539
The risk or severity of tendinopathy can be increased when Hydrocortisone acetate is combined with Flumequine.
DB14541
The risk or severity of tendinopathy can be increased when Hydrocortisone cypionate is combined with Flumequine.
DB14545
The risk or severity of tendinopathy can be increased when Hydrocortisone succinate is combined with Flumequine.
DB14631
The risk or severity of tendinopathy can be increased when Prednisolone phosphate is combined with Flumequine.
DB14633
The risk or severity of tendinopathy can be increased when Prednisolone hemisuccinate is combined with Flumequine.
DB14644
The risk or severity of tendinopathy can be increased when Methylprednisolone hemisuccinate is combined with Flumequine.
DB14646
The risk or severity of tendinopathy can be increased when Prednisone acetate is combined with Flumequine.
DB14652
The risk or severity of tendinopathy can be increased when Clocortolone acetate is combined with Flumequine.
DB14659
The risk or severity of tendinopathy can be increased when Melengestrol acetate is combined with Flumequine.
DB14669
The risk or severity of tendinopathy can be increased when Betamethasone phosphate is combined with Flumequine.
DB14681
The risk or severity of tendinopathy can be increased when Cortisone is combined with Flumequine.
DB01013
The risk or severity of tendinopathy can be increased when Clobetasol propionate is combined with Flumequine.
DB01047
The risk or severity of tendinopathy can be increased when Fluocinonide is combined with Flumequine.
DB14540
The risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Flumequine.
DB00547
The risk or severity of tendinopathy can be increased when Desoximetasone is combined with Flumequine.
DB00764
The risk or severity of tendinopathy can be increased when Mometasone is combined with Flumequine.
DB08971
The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Flumequine.
DB11750
The risk or severity of tendinopathy can be increased when Clobetasol is combined with Flumequine.
DB15566
The risk or severity of tendinopathy can be increased when Prednisolone acetate is combined with Flumequine.
DB09095
The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Flumequine.
DB00653
Magnesium sulfate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01397
Magnesium salicylate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB08938
Magaldrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09407
Magnesium chloride can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09511
Talc can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11110
Magnesium citrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13322
Hydrotalcite can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13359
Magnesium aspartate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13749
Magnesium gluconate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13786
Magnesium orotate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14514
Magnesium levulinate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14515
Magnesium lactate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01377
Magnesium oxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09104
Magnesium hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09281
Magnesium trisilicate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09481
Magnesium carbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13249
Magnesium silicate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13486
Magnesium peroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01593
Zinc can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB02165
Zinc trihydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB04249
Zinc Substituted Heme C can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09221
Polaprezinc can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09321
Zinc oxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09322
Zinc sulfate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11154
Zinc citrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11175
Zinc picolinate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11248
Zinc gluconate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14479
Acetylcysteine zinc can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14485
Zinc ascorbate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14487
Zinc acetate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14493
Zinc glycinate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14533
Zinc chloride can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14548
Zinc sulfate, unspecified form can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14532
Zinc cation can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06723
Aluminum hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13280
Aluminium acetoacetate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13595
Almasilate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13626
Aluminium glycinate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14517
Aluminium phosphate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00325
Nitroprusside can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB01592
Iron can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06215
Ferumoxytol can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB06783
Prussian blue can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09501
Ferric ammonium citrate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09507
Ferumoxsil can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB09508
Ferumoxides can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11210
Ferrous bisglycinate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11417
Gleptoferron can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB11576
Ferric oxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12821
Perflubutane can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13257
Ferrous sulfate anhydrous can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13423
Ferric hydroxide can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13569
Ferrous chloride can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14488
Ferrous gluconate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14489
Ferrous succinate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB14491
Ferrous fumarate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB13381
Sodium feredetate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB15598
Ferric maltol can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB12208
Iron isomaltoside 1000 can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00007
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Leuprolide.
DB00014
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Goserelin.
DB00195
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Betaxolol.
DB00199
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Erythromycin.
DB00207
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Azithromycin.
DB00218
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Moxifloxacin.
DB00243
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ranolazine.
DB00333
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Methadone.
DB00343
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Diltiazem.
DB00363
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Clozapine.
DB00391
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Sulpiride.
DB00393
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Nimodipine.
DB00420
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Promazine.
DB00433
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Prochlorperazine.
DB00450
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Droperidol.
DB00477
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Chlorpromazine.
DB00526
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Oxaliplatin.
DB00537
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ciprofloxacin.
DB00556
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Perflutren.
DB00568
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Cinnarizine.
DB00571
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Propranolol.
DB00572
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Atropine.
DB00608
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Chloroquine.
DB00625
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Efavirenz.
DB00640
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Adenosine.
DB00743
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Gadobenic acid.
DB00748
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Carbinoxamine.
DB00757
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dolasetron.
DB00778
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Roxithromycin.
DB00779
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Nalidixic acid.
DB00827
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Cinoxacin.
DB00836
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Loperamide.
DB00889
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Granisetron.
DB00904
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ondansetron.
DB00922
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Levosimendan.
DB00933
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Mesoridazine.
DB00967
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Desloratadine.
DB00976
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Telithromycin.
DB00978
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Lomefloxacin.
DB00985
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dimenhydrinate.
DB01087
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Primaquine.
DB01113
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Papaverine.
DB01114
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Chlorpheniramine.
DB01115
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Nifedipine.
DB01137
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Levofloxacin.
DB01155
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Gemifloxacin.
DB01165
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ofloxacin.
DB01182
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Propafenone.
DB01193
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Acebutolol.
DB01195
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Flecainide.
DB01211
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Clarithromycin.
DB01227
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Levacetylmethadol.
DB01232
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Saquinavir.
DB01388
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Mibefradil.
DB01580
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Oxprenolol.
DB01599
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Probucol.
DB01615
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Aceprometazine.
DB02638
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Terlipressin.
DB04825
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Prenylamine.
DB04842
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Fluspirilene.
DB04957
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Azimilide.
DB05223
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Pracinostat.
DB05488
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Technetium Tc-99m ciprofloxacin.
DB06160
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Garenoxacin.
DB06200
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Tedisamil.
DB06334
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Tucidinostat.
DB06402
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Telavancin.
DB06589
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Pazopanib.
DB06600
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Nemonoxacin.
DB06603
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Panobinostat.
DB06712
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Nilvadipine.
DB08799
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Antazoline.
DB08865
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Crizotinib.
DB08903
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Bedaquiline.
DB08952
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Indenolol.
DB08980
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Fendiline.
DB08992
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Eperisone.
DB09016
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Butriptyline.
DB09063
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ceritinib.
DB09078
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Lenvatinib.
DB09224
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Melperone.
DB09231
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Benidipine.
DB09555
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dexchlorpheniramine maleate.
DB11640
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Amifampridine.
DB11830
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Mocetinostat.
DB11841
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Entinostat.
DB12141
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Gilteritinib.
DB12174
The risk or severity of QTc prolongation can be increased when Flumequine is combined with CUDC-101.
DB12286
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Simendan.
DB12376
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ricolinostat.
DB12523
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Mizolastine.
DB12565
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Abexinostat.
DB12877
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Oxatomide.
DB13261
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Sitafloxacin.
DB13273
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Sultopride.
DB13500
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Otilonium.
DB13546
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Nizofenone.
DB13652
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Bunaftine.
DB13653
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Lorcainide.
DB13679
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dexchlorpheniramine.
DB13791
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Penfluridol.
DB14063
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dexverapamil.
DB14568
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ivosidenib.
DB01224
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Quetiapine.
DB11718
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Encorafenib.
DB01084
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Emedastine.
DB15982
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Berotralstat.
DB00204
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dofetilide.
DB00215
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Citalopram.
DB00280
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Disopyramide.
DB00283
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Clemastine.
DB00308
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ibutilide.
DB00313
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Valproic acid.
DB00342
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Terfenadine.
DB00365
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Grepafloxacin.
DB00468
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Quinine.
DB00489
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Sotalol.
DB00539
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Toremifene.
DB00604
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Cisapride.
DB00619
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Imatinib.
DB00637
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Astemizole.
DB00679
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Thioridazine.
DB00685
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Trovafloxacin.
DB00834
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Mifepristone.
DB00875
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Flupentixol.
DB00907
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Cocaine.
DB00908
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Quinidine.
DB01035
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Procainamide.
DB01169
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Arsenic trioxide.
DB01175
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Escitalopram.
DB01184
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Domperidone.
DB01208
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Sparfloxacin.
DB01218
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Halofantrine.
DB01244
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Bepridil.
DB01267
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Paliperidone.
DB01356
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Lithium cation.
DB01405
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Temafloxacin.
DB01624
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Zuclopenthixol.
DB04844
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Tetrabenazine.
DB04855
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dronedarone.
DB04868
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Nilotinib.
DB04946
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Iloperidone.
DB05294
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Vandetanib.
DB06176
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Romidepsin.
DB06216
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Asenapine.
DB06697
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Artemether.
DB06708
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Lumefantrine.
DB09039
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Eliglustat.
DB09083
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ivabradine.
DB11730
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ribociclib.
DB11978
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Glasdegib.
DB12161
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Deutetrabenazine.
DB13074
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Macimorelin.
DB13725
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Terodiline.
DB01118
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Amiodarone.
DB00201
The metabolism of Caffeine can be decreased when combined with Flumequine.
DB00651
The metabolism of Dyphylline can be decreased when combined with Flumequine.
DB00806
The metabolism of Pentoxifylline can be decreased when combined with Flumequine.
DB01033
The metabolism of Mercaptopurine can be decreased when combined with Flumequine.
DB01303
The metabolism of Oxtriphylline can be decreased when combined with Flumequine.
DB01412
The metabolism of Theobromine can be decreased when combined with Flumequine.
DB01482
The metabolism of Fenethylline can be decreased when combined with Flumequine.
DB01667
The metabolism of 8-azaguanine can be decreased when combined with Flumequine.
DB01978
The metabolism of 7,9-Dimethylguanine can be decreased when combined with Flumequine.
DB02134
The metabolism of Xanthine can be decreased when combined with Flumequine.
DB02245
The metabolism of 7-Deazaguanine can be decreased when combined with Flumequine.
DB02377
The metabolism of Guanine can be decreased when combined with Flumequine.
DB02489
The metabolism of 9-Methylguanine can be decreased when combined with Flumequine.
DB02568
The metabolism of Peldesine can be decreased when combined with Flumequine.
DB04076
The metabolism of Hypoxanthine can be decreased when combined with Flumequine.
DB04356
The metabolism of 9-Deazaguanine can be decreased when combined with Flumequine.
DB06479
The metabolism of Propentofylline can be decreased when combined with Flumequine.
DB06575
The metabolism of Valomaciclovir can be decreased when combined with Flumequine.
DB07954
The metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Flumequine.
DB08844
The metabolism of Uric acid can be decreased when combined with Flumequine.
DB09273
The metabolism of Doxofylline can be decreased when combined with Flumequine.
DB11919
The metabolism of 6-O-benzylguanine can be decreased when combined with Flumequine.
DB12406
The metabolism of Lisofylline can be decreased when combined with Flumequine.
DB12531
The metabolism of Lobucavir can be decreased when combined with Flumequine.
DB12926
The metabolism of Cafedrine can be decreased when combined with Flumequine.
DB12927
The metabolism of Theodrenaline can be decreased when combined with Flumequine.
DB13203
The metabolism of Bamifylline can be decreased when combined with Flumequine.
DB13449
The metabolism of Proxyphylline can be decreased when combined with Flumequine.
DB13573
The metabolism of Acefylline can be decreased when combined with Flumequine.
DB13592
The metabolism of Etamiphylline can be decreased when combined with Flumequine.
DB13634
The metabolism of Pentifylline can be decreased when combined with Flumequine.
DB13812
The metabolism of Bufylline can be decreased when combined with Flumequine.
DB14018
The metabolism of Bromotheophylline can be decreased when combined with Flumequine.
DB14029
The metabolism of Furafylline can be decreased when combined with Flumequine.
DB14132
The metabolism of 8-chlorotheophylline can be decreased when combined with Flumequine.
DB15122
The metabolism of PCS-499 can be decreased when combined with Flumequine.
DB00277
The metabolism of Theophylline can be decreased when combined with Flumequine.
DB01223
The metabolism of Aminophylline can be decreased when combined with Flumequine.
DB12768
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Flumequine.
DB14022
The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Flumequine.
DB08881
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Vemurafenib.
DB11637
Flumequine may increase the QTc-prolonging activities of Delamanid.
DB00104
The risk or severity of QTc prolongation can be increased when Octreotide is combined with Flumequine.
DB00107
The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Flumequine.
DB00187
The risk or severity of QTc prolongation can be increased when Esmolol is combined with Flumequine.
DB00196
The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Flumequine.
DB00220
The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Flumequine.
DB00230
The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Flumequine.
DB00245
The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Flumequine.
DB00270
The risk or severity of QTc prolongation can be increased when Isradipine is combined with Flumequine.
DB00285
The risk or severity of QTc prolongation can be increased when Venlafaxine is combined with Flumequine.
DB00289
The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Flumequine.
DB00341
The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Flumequine.
DB00344
The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Flumequine.
DB00346
The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Flumequine.
DB00347
The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Flumequine.
DB00354
The risk or severity of QTc prolongation can be increased when Buclizine is combined with Flumequine.
DB00358
The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Flumequine.
DB00366
The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Flumequine.
DB00373
The risk or severity of QTc prolongation can be increased when Timolol is combined with Flumequine.
DB00374
The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Flumequine.
DB00390
The risk or severity of QTc prolongation can be increased when Digoxin is combined with Flumequine.
DB00405
The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Flumequine.
DB00424
The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Flumequine.
DB00427
The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Flumequine.
DB00434
The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Flumequine.
DB00467
The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Flumequine.
DB00487
The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Flumequine.
DB00503
The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Flumequine.
DB00529
The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Flumequine.
DB00543
The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Flumequine.
DB00555
The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Flumequine.
DB00582
The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Flumequine.
DB00593
The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Flumequine.
DB00613
The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Flumequine.
DB00622
The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Flumequine.
DB00674
The risk or severity of QTc prolongation can be increased when Galantamine is combined with Flumequine.
DB00678
The risk or severity of QTc prolongation can be increased when Losartan is combined with Flumequine.
DB00680
The risk or severity of QTc prolongation can be increased when Moricizine is combined with Flumequine.
DB00691
The risk or severity of QTc prolongation can be increased when Moexipril is combined with Flumequine.
DB00710
The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Flumequine.
DB00714
The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Flumequine.
DB00719
The risk or severity of QTc prolongation can be increased when Azatadine is combined with Flumequine.
DB00726
The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Flumequine.
DB00734
The risk or severity of QTc prolongation can be increased when Risperidone is combined with Flumequine.
DB00753
The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Flumequine.
DB00808
The risk or severity of QTc prolongation can be increased when Indapamide is combined with Flumequine.
DB00817
The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Flumequine.
DB00818
The risk or severity of QTc prolongation can be increased when Propofol is combined with Flumequine.
DB00822
The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Flumequine.
DB00825
The risk or severity of QTc prolongation can be increased when Levomenthol is combined with Flumequine.
DB00835
The risk or severity of QTc prolongation can be increased when Brompheniramine is combined with Flumequine.
DB00862
The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Flumequine.
DB00864
The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Flumequine.
DB00871
The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Flumequine.
DB00909
The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Flumequine.
DB00915
The risk or severity of QTc prolongation can be increased when Amantadine is combined with Flumequine.
DB00916
The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Flumequine.
DB00920
The risk or severity of QTc prolongation can be increased when Ketotifen is combined with Flumequine.
DB00927
The risk or severity of QTc prolongation can be increased when Famotidine is combined with Flumequine.
DB00938
The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Flumequine.
DB00949
The risk or severity of QTc prolongation can be increased when Felbamate is combined with Flumequine.
DB00983
The risk or severity of QTc prolongation can be increased when Formoterol is combined with Flumequine.
DB00999
The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Flumequine.
DB01001
The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Flumequine.
DB01023
The risk or severity of QTc prolongation can be increased when Felodipine is combined with Flumequine.
DB01026
The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Flumequine.
DB01036
The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Flumequine.
DB01044
The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Flumequine.
DB01054
The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Flumequine.
DB01059
The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Flumequine.
DB01069
The risk or severity of QTc prolongation can be increased when Promethazine is combined with Flumequine.
DB01071
The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Flumequine.
DB01072
The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Flumequine.
DB01074
The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Flumequine.
DB01075
The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Flumequine.
DB01106
The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Flumequine.
DB01158
The risk or severity of QTc prolongation can be increased when Bretylium is combined with Flumequine.
DB01167
The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Flumequine.
DB01173
The risk or severity of QTc prolongation can be increased when Orphenadrine is combined with Flumequine.
DB01176
The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Flumequine.
DB01189
The risk or severity of QTc prolongation can be increased when Desflurane is combined with Flumequine.
DB01228
The risk or severity of QTc prolongation can be increased when Encainide is combined with Flumequine.
DB01236
The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Flumequine.
DB01238
The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Flumequine.
DB01239
The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Flumequine.
DB01246
The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Flumequine.
DB01259
The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Flumequine.
DB01263
The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Flumequine.
DB01274
The risk or severity of QTc prolongation can be increased when Arformoterol is combined with Flumequine.
DB01396
The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Flumequine.
DB01403
The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Flumequine.
DB01426
The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Flumequine.
DB01591
The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Flumequine.
DB01611
The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Flumequine.
DB01620
The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Flumequine.
DB02546
The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Flumequine.
DB04576
The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Flumequine.
DB04695
The risk or severity of QTc prolongation can be increased when Farnesyl thiopyrophosphate is combined with Flumequine.
DB04846
The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Flumequine.
DB04953
The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Flumequine.
DB05039
The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Flumequine.
DB05246
The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Flumequine.
DB05465
The risk or severity of QTc prolongation can be increased when Tandutinib is combined with Flumequine.
DB06217
The risk or severity of QTc prolongation can be increased when Vernakalant is combined with Flumequine.
DB06282
The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Flumequine.
DB06288
The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Flumequine.
DB06468
The risk or severity of QTc prolongation can be increased when Cariporide is combined with Flumequine.
DB06663
The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Flumequine.
DB06691
The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Flumequine.
DB06699
The risk or severity of QTc prolongation can be increased when Degarelix is combined with Flumequine.
DB06719
The risk or severity of QTc prolongation can be increased when Buserelin is combined with Flumequine.
DB06788
The risk or severity of QTc prolongation can be increased when Histrelin is combined with Flumequine.
DB06825
The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Flumequine.
DB07780
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Flumequine.
DB07841
The risk or severity of QTc prolongation can be increased when Geranylgeranyl diphosphate is combined with Flumequine.
DB08808
The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Flumequine.
DB08815
The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Flumequine.
DB08864
The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Flumequine.
DB08871
The risk or severity of QTc prolongation can be increased when Eribulin is combined with Flumequine.
DB08893
The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Flumequine.
DB08912
The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Flumequine.
DB08936
The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Flumequine.
DB09080
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Olodaterol.
DB09082
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Vilanterol.
DB09089
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Trimebutine.
DB09090
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Pinaverium.
DB09167
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dosulepin.
DB09229
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Aranidipine.
DB09235
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Efonidipine.
DB09236
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Lacidipine.
DB09239
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Niguldipine.
DB09488
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Acrivastine.
DB11390
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Coumaphos.
DB11397
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Dichlorvos.
DB11408
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Famphur.
DB11412
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Fenthion.
DB11443
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Orbifloxacin.
DB11448
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Phosmet.
DB11491
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Sarafloxacin.
DB11511
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Difloxacin.
DB11591
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Bilastine.
DB11614
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Rupatadine.
DB11742
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ebastine.
DB11770
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Talinolol.
DB11774
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Pazufloxacin.
DB11785
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Anisodamine.
DB11891
The risk or severity of QTc prolongation can be increased when Flumequine is combined with CUDC-907.
DB11892
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Prulifloxacin.
DB11943
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Delafloxacin.
DB12093
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Tetrahydropalmatine.
DB12231
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Temefos.
DB12645
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Givinostat.
DB12712
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Pilsicainide.
DB12766
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Cicletanine.
DB12923
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Gallopamil.
DB13358
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Cibenzoline.
DB13488
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Bencyclane.
DB13555
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Prajmaline.
DB13627
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Oxolinic acid.
DB13651
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Lorajmine.
DB13691
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Acetyldigoxin.
DB13744
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Piromidic acid.
DB13766
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Lidoflazine.
DB13772
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Rufloxacin.
DB13823
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Pipemidic acid.
DB14185
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Aripiprazole lauroxil.
DB14713
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Inotersen.
DB01601
The risk or severity of QTc prolongation can be increased when Lopinavir is combined with Flumequine.
DB00845
The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Flumequine.
DB11796
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Fostemsavir.
DB00540
The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Flumequine.
DB01151
The risk or severity of QTc prolongation can be increased when Desipramine is combined with Flumequine.
DB00751
The risk or severity of QTc prolongation can be increased when Epinastine is combined with Flumequine.
DB11853
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Relugolix.
DB01233
The metabolism of Flumequine can be decreased when combined with Metoclopramide.
DB00176
The metabolism of Fluvoxamine can be decreased when combined with Flumequine.
DB00184
The metabolism of Nicotine can be decreased when combined with Flumequine.
DB00188
The metabolism of Bortezomib can be decreased when combined with Flumequine.
DB00262
The metabolism of Carmustine can be decreased when combined with Flumequine.
DB00281
The metabolism of Lidocaine can be decreased when combined with Flumequine.
DB00286
The metabolism of Conjugated estrogens can be decreased when combined with Flumequine.
DB00296
The metabolism of Ropivacaine can be decreased when combined with Flumequine.
DB00316
The metabolism of Acetaminophen can be decreased when combined with Flumequine.
DB00334
The metabolism of Olanzapine can be decreased when combined with Flumequine.
DB00356
The metabolism of Chlorzoxazone can be decreased when combined with Flumequine.
DB00370
The metabolism of Mirtazapine can be decreased when combined with Flumequine.
DB00379
The metabolism of Mexiletine can be decreased when combined with Flumequine.
DB00382
The metabolism of Tacrine can be decreased when combined with Flumequine.
DB00384
The metabolism of Triamterene can be decreased when combined with Flumequine.
DB00425
The metabolism of Zolpidem can be decreased when combined with Flumequine.
DB00442
The metabolism of Entecavir can be decreased when combined with Flumequine.
DB00461
The metabolism of Nabumetone can be decreased when combined with Flumequine.
DB00476
The metabolism of Duloxetine can be decreased when combined with Flumequine.
DB00499
The metabolism of Flutamide can be decreased when combined with Flumequine.
DB00518
The metabolism of Albendazole can be decreased when combined with Flumequine.
DB00533
The metabolism of Rofecoxib can be decreased when combined with Flumequine.
DB00586
The metabolism of Diclofenac can be decreased when combined with Flumequine.
DB00629
The metabolism of Guanabenz can be decreased when combined with Flumequine.
DB00642
The metabolism of Pemetrexed can be decreased when combined with Flumequine.
DB00661
The metabolism of Verapamil can be decreased when combined with Flumequine.
DB00715
The metabolism of Paroxetine can be decreased when combined with Flumequine.
DB00730
The metabolism of Thiabendazole can be decreased when combined with Flumequine.
DB00740
The metabolism of Riluzole can be decreased when combined with Flumequine.
DB00744
The metabolism of Zileuton can be decreased when combined with Flumequine.
DB00758
The metabolism of Clopidogrel can be decreased when combined with Flumequine.
DB00783
The metabolism of Estradiol can be decreased when combined with Flumequine.
DB00787
The metabolism of Acyclovir can be decreased when combined with Flumequine.
DB00788
The metabolism of Naproxen can be decreased when combined with Flumequine.
DB00831
The metabolism of Trifluoperazine can be decreased when combined with Flumequine.
DB00850
The metabolism of Perphenazine can be decreased when combined with Flumequine.
DB00857
The metabolism of Terbinafine can be decreased when combined with Flumequine.
DB00863
The metabolism of Ranitidine can be decreased when combined with Flumequine.
DB00898
The metabolism of Ethanol can be decreased when combined with Flumequine.
DB00934
The metabolism of Maprotiline can be decreased when combined with Flumequine.
DB00969
The metabolism of Alosetron can be decreased when combined with Flumequine.
DB00980
The metabolism of Ramelteon can be decreased when combined with Flumequine.
DB00993
The metabolism of Azathioprine can be decreased when combined with Flumequine.
DB00998
The metabolism of Frovatriptan can be decreased when combined with Flumequine.
DB01002
The metabolism of Levobupivacaine can be decreased when combined with Flumequine.
DB01012
The metabolism of Cinacalcet can be decreased when combined with Flumequine.
DB01037
The metabolism of Selegiline can be decreased when combined with Flumequine.
DB01056
The metabolism of Tocainide can be decreased when combined with Flumequine.
DB01058
The metabolism of Praziquantel can be decreased when combined with Flumequine.
DB01065
The metabolism of Melatonin can be decreased when combined with Flumequine.
DB01094
The metabolism of Hesperetin can be decreased when combined with Flumequine.
DB01097
The metabolism of Leflunomide can be decreased when combined with Flumequine.
DB01136
The metabolism of Carvedilol can be decreased when combined with Flumequine.
DB01166
The metabolism of Cilostazol can be decreased when combined with Flumequine.
DB01191
The metabolism of Dexfenfluramine can be decreased when combined with Flumequine.
DB01367
The metabolism of Rasagiline can be decreased when combined with Flumequine.
DB01424
The metabolism of Aminophenazone can be decreased when combined with Flumequine.
DB01435
The metabolism of Antipyrine can be decreased when combined with Flumequine.
DB01558
The metabolism of Bromazepam can be decreased when combined with Flumequine.
DB01623
The metabolism of Thiothixene can be decreased when combined with Flumequine.
DB01628
The metabolism of Etoricoxib can be decreased when combined with Flumequine.
DB01645
The metabolism of Genistein can be decreased when combined with Flumequine.
DB02709
The metabolism of Resveratrol can be decreased when combined with Flumequine.
DB03783
The metabolism of Phenacetin can be decreased when combined with Flumequine.
DB04574
The metabolism of Estrone sulfate can be decreased when combined with Flumequine.
DB04841
The metabolism of Flunarizine can be decreased when combined with Flumequine.
DB04871
The metabolism of Lorcaserin can be decreased when combined with Flumequine.
DB04948
The metabolism of Lofexidine can be decreased when combined with Flumequine.
DB04951
The metabolism of Pirfenidone can be decreased when combined with Flumequine.
DB05676
The metabolism of Apremilast can be decreased when combined with Flumequine.
DB06148
The metabolism of Mianserin can be decreased when combined with Flumequine.
DB06210
The metabolism of Eltrombopag can be decreased when combined with Flumequine.
DB06235
The metabolism of Vadimezan can be decreased when combined with Flumequine.
DB06594
The metabolism of Agomelatine can be decreased when combined with Flumequine.
DB06770
The metabolism of Benzyl alcohol can be decreased when combined with Flumequine.
DB06774
The metabolism of Capsaicin can be decreased when combined with Flumequine.
DB08883
The metabolism of Perampanel can be decreased when combined with Flumequine.
DB09071
The metabolism of Tasimelteon can be decreased when combined with Flumequine.
DB09118
The metabolism of Stiripentol can be decreased when combined with Flumequine.
DB09225
The metabolism of Zotepine can be decreased when combined with Flumequine.
DB09288
The metabolism of Propacetamol can be decreased when combined with Flumequine.
DB09290
The metabolism of Ramosetron can be decreased when combined with Flumequine.
DB11967
The metabolism of Binimetinib can be decreased when combined with Flumequine.
DB12026
The metabolism of Voxilaprevir can be decreased when combined with Flumequine.
DB12245
The metabolism of Triclabendazole can be decreased when combined with Flumequine.
DB12332
The metabolism of Rucaparib can be decreased when combined with Flumequine.
DB12945
The metabolism of Dihydralazine can be decreased when combined with Flumequine.
DB13952
The metabolism of Estradiol acetate can be decreased when combined with Flumequine.
DB13953
The metabolism of Estradiol benzoate can be decreased when combined with Flumequine.
DB13954
The metabolism of Estradiol cypionate can be decreased when combined with Flumequine.
DB13955
The metabolism of Estradiol dienanthate can be decreased when combined with Flumequine.
DB13956
The metabolism of Estradiol valerate can be decreased when combined with Flumequine.
DB11757
The metabolism of Istradefylline can be decreased when combined with Flumequine.
DB00972
The metabolism of Azelastine can be decreased when combined with Flumequine.
DB04889
The metabolism of Bicifadine can be decreased when combined with Flumequine.
DB05708
The metabolism of GTS-21 can be decreased when combined with Flumequine.
DB00977
The metabolism of Ethinylestradiol can be decreased when combined with Flumequine.
DB01142
The metabolism of Doxepin can be decreased when combined with Flumequine.
DB00532
The metabolism of Mephenytoin can be decreased when combined with Flumequine.
DB00924
The metabolism of Cyclobenzaprine can be decreased when combined with Flumequine.
DB11689
The metabolism of Selumetinib can be decreased when combined with Flumequine.
DB00655
The metabolism of Estrone can be decreased when combined with Flumequine.
DB00299
The metabolism of Penciclovir can be decreased when combined with Flumequine.
DB00544
The metabolism of Fluorouracil can be decreased when combined with Flumequine.
DB00261
The metabolism of Anagrelide can be decreased when combined with Flumequine.
DB00530
The metabolism of Erlotinib can be decreased when combined with Flumequine.
DB01100
The metabolism of Pimozide can be decreased when combined with Flumequine.
DB00675
The metabolism of Flumequine can be decreased when combined with Tamoxifen.
DB00697
The metabolism of Tizanidine can be decreased when combined with Flumequine.
DB00398
The metabolism of Sorafenib can be decreased when combined with Flumequine.
DB00773
The metabolism of Etoposide can be decreased when combined with Flumequine.
DB00851
The metabolism of Dacarbazine can be decreased when combined with Flumequine.
DB01254
The metabolism of Dasatinib can be decreased when combined with Flumequine.
DB06626
The metabolism of Axitinib can be decreased when combined with Flumequine.
DB06769
The metabolism of Bendamustine can be decreased when combined with Flumequine.
DB08910
The metabolism of Pomalidomide can be decreased when combined with Flumequine.
DB09256
The metabolism of Tegafur can be decreased when combined with Flumequine.
DB13874
The metabolism of Enasidenib can be decreased when combined with Flumequine.
DB00458
The metabolism of Imipramine can be decreased when combined with Flumequine.
DB00575
The metabolism of Clonidine can be decreased when combined with Flumequine.
DB01242
The metabolism of Clomipramine can be decreased when combined with Flumequine.
DB00301
The serum concentration of Flumequine can be increased when it is combined with Flucloxacillin.
DB00319
The serum concentration of Flumequine can be increased when it is combined with Piperacillin.
DB00415
The serum concentration of Flumequine can be increased when it is combined with Ampicillin.
DB00417
The serum concentration of Flumequine can be increased when it is combined with Phenoxymethylpenicillin.
DB00485
The serum concentration of Flumequine can be increased when it is combined with Dicloxacillin.
DB00578
The serum concentration of Flumequine can be increased when it is combined with Carbenicillin.
DB00607
The serum concentration of Flumequine can be increased when it is combined with Nafcillin.
DB00713
The serum concentration of Flumequine can be increased when it is combined with Oxacillin.
DB00739
The serum concentration of Flumequine can be increased when it is combined with Hetacillin.
DB00895
The serum concentration of Flumequine can be increased when it is combined with Benzylpenicilloyl polylysine.
DB00948
The serum concentration of Flumequine can be increased when it is combined with Mezlocillin.
DB01000
The serum concentration of Flumequine can be increased when it is combined with Cyclacillin.
DB01053
The serum concentration of Flumequine can be increased when it is combined with Benzylpenicillin.
DB01060
The serum concentration of Flumequine can be increased when it is combined with Amoxicillin.
DB01061
The serum concentration of Flumequine can be increased when it is combined with Azlocillin.
DB01147
The serum concentration of Flumequine can be increased when it is combined with Cloxacillin.
DB01163
The serum concentration of Flumequine can be increased when it is combined with Amdinocillin.
DB01602
The serum concentration of Flumequine can be increased when it is combined with Bacampicillin.
DB01603
The serum concentration of Flumequine can be increased when it is combined with Meticillin.
DB01604
The serum concentration of Flumequine can be increased when it is combined with Pivampicillin.
DB01605
The serum concentration of Flumequine can be increased when it is combined with Pivmecillinam.
DB01607
The serum concentration of Flumequine can be increased when it is combined with Ticarcillin.
DB08795
The serum concentration of Flumequine can be increased when it is combined with Azidocillin.
DB09319
The serum concentration of Flumequine can be increased when it is combined with Carindacillin.
DB09320
The serum concentration of Flumequine can be increased when it is combined with Procaine benzylpenicillin.
DB12127
The serum concentration of Flumequine can be increased when it is combined with Sultamicillin.
DB12343
The serum concentration of Flumequine can be increased when it is combined with Temocillin.
DB13300
The serum concentration of Flumequine can be increased when it is combined with Epicillin.
DB13337
The serum concentration of Flumequine can be increased when it is combined with Pheneticillin.
DB13506
The serum concentration of Flumequine can be increased when it is combined with Carfecillin.
DB13660
The serum concentration of Flumequine can be increased when it is combined with Propicillin.
DB13686
The serum concentration of Flumequine can be increased when it is combined with Clometocillin.
DB13693
The serum concentration of Flumequine can be increased when it is combined with Sulbenicillin.
DB13739
The serum concentration of Flumequine can be increased when it is combined with Penamecillin.
DB13814
The serum concentration of Flumequine can be increased when it is combined with Talampicillin.
DB13816
The serum concentration of Flumequine can be increased when it is combined with Aspoxicillin.
DB13836
The serum concentration of Flumequine can be increased when it is combined with Metampicillin.
DB00321
Flumequine may increase the QTc-prolonging activities of Amitriptyline.
DB00091
The risk or severity of nephrotoxicity can be increased when Flumequine is combined with Cyclosporine.
DB00268
The risk or severity of adverse effects can be increased when Flumequine is combined with Ropinirole.
DB00581
The therapeutic efficacy of Lactulose can be decreased when used in combination with Flumequine.
DB00656
The risk or severity of QTc prolongation can be increased when Trazodone is combined with Flumequine.
DB11986
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Entrectinib.
DB11642
Flumequine may increase the QTc-prolonging activities of Pitolisant.
DB12825
Lefamulin may increase the QTc-prolonging activities of Flumequine.
DB00557
The risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Flumequine.
DB00246
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Ziprasidone.
DB14513
Magnesium can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.
DB00502
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Haloperidol.
DB14443
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Flumequine.
DB00472
The risk or severity of QTc prolongation can be increased when Flumequine is combined with Fluoxetine.

序列

实验性质

外部标识符

resource：ChEBI
identifier：85269
resource：PubChem Compound
identifier：3374
resource：PubChem Substance
identifier：310264935
resource：ChemSpider
identifier：3257
resource：Wikipedia
identifier：Flumequine
resource：ChEMBL
identifier：CHEMBL370252
resource：RxCUI
identifier：25112

外部链接

路径

目标

酶

BE0002433Cytochrome P450 1A2HumansinhibitorA3928518466106Gunes A, Dahl ML: Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics. 2008 May;9(5):625-37. doi: 10.2217/14622416.9.5.625.A3928726838075Liu L, Miao MX, Zhong ZY, Xu P, Chen Y, Liu XD: Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats. Acta Pharmacol Sin. 2016 Apr;37(4):561-70. doi: 10.1038/aps.2015.160. Epub 2016 Feb 1.F1801Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/801/original/Determination_of_the_inhibitory_potential_of_6_fluoroquinolones_on_CYP1A2_and_CYP2C9_in_human_liver_.pdf?1539203695F1802FDA label, ciprofloxacin//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/802/original/Ciprofloxacin_FDA.pdf?1539203799unknownCytochrome P450 1A2Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N3-demethylation. Also acts in the metabolism of aflatoxin B1 and acetaminophen. Participates in the bioactivation of carcinogenic aromatic and heterocyclic amines. Catalizes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin.CYP1A215q24Endoplasmic reticulum membrane9.4358293.7615HumansHUGO Gene Nomenclature Committee (HGNC)HGNC:2596GenAtlasCYP1A2GenBank Gene DatabaseZ00036Guide to Pharmacology1319UniProtKBP05177UniProt AccessionCP1A2_HUMAN1.14.14.1Cholesterol 25-hydroxylaseCYPIA2Cytochrome P(3)450Cytochrome P450 4Cytochrome P450-P3>lcl|BSEQ0004778|Cytochrome P450 1A2 MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE FSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN>lcl|BSEQ0011742|Cytochrome P450 1A2 (CYP1A2) ATGGCATTGTCCCAGTCTGTTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCTGCCATC TTCTGCCTGGTATTCTGGGTGCTCAAGGGTTTGAGGCCTCGGGTCCCCAAAGGCCTGAAA AGTCCACCAGAGCCATGGGGCTGGCCCTTGCTCGGGCATGTGCTGACCCTGGGGAAGAAC CCGCACCTGGCACTGTCAAGGATGAGCCAGCGCTACGGGGACGTCCTGCAGATCCGCATT GGCTCCACGCCCGTGCTGGTGCTGAGCCGCCTGGACACCATCCGGCAGGCCCTGGTGCGG CAGGGCGACGATTTCAAGGGCCGGCCTGACCTCTACACCTCCACCCTCATCACTGATGGC CAGAGCTTGACCTTCAGCACAGACTCTGGACCGGTGTGGGCTGCCCGCCGGCGCCTGGCC CAGAATGCCCTCAACACCTTCTCCATCGCCTCTGACCCAGCTTCCTCATCCTCCTGCTAC CTGGAGGAGCATGTGAGCAAGGAGGCTAAGGCCCTGATCAGCAGGTTGCAGGAGCTGATG GCAGGGCCTGGGCACTTCGACCCTTACAATCAGGTGGTGGTGTCAGTGGCCAACGTCATT GGTGCCATGTGCTTCGGACAGCACTTCCCTGAGAGTAGCGATGAGATGCTCAGCCTCGTG AAGAACACTCATGAGTTCGTGGAGACTGCCTCCTCCGGGAACCCCCTGGACTTCTTCCCC ATCCTTCGCTACCTGCCTAACCCTGCCCTGCAGAGGTTCAAGGCCTTCAACCAGAGGTTC CTGTGGTTCCTGCAGAAAACAGTCCAGGAGCACTATCAGGACTTTGACAAGAACAGTGTC CGGGACATCACGGGTGCCCTGTTCAAGCACAGCAAGAAGGGGCCTAGAGCCAGCGGCAAC CTCATCCCACAGGAGAAGATTGTCAACCTTGTCAATGACATCTTTGGAGCAGGATTTGAC ACAGTCACCACAGCCATCTCCTGGAGCCTCATGTACCTTGTGACCAAGCCTGAGATACAG AGGAAGATCCAGAAGGAGCTGGACACTGTGATTGGCAGGGAGCGGCGGCCCCGGCTCTCT GACAGACCCCAGCTGCCCTACTTGGAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCC TTCTTGCCCTTCACCATCCCCCACAGCACAACAAGGGACACAACGCTGAATGGCTTCTAC ATCCCCAAGAAATGCTGTGTCTTCGTAAACCAGTGGCAGGTCAACCATGACCCAGAGCTG TGGGAGGACCCCTCTGAGTTCCGGCCTGAGCGGTTCCTCACCGCCGATGGCACTGCCATT AACAAGCCCTTGAGTGAGAAGATGATGCTGTTTGGCATGGGCAAGCGCCGGTGTATCGGG GAAGTCCTGGCCAAGTGGGAGATCTTCCTCTTCCTGGCCATCCTGCTACAGCAACTGGAG TTCAGCGTGCCGCCGGGCGTGAAAGTCGACCTGACCCCCATCTACGGGCTGACCATGAAG CACGCCCGCTGTGAACATGTCCAGGCGCGGCTGCGCTTCTCCATCAATTGAPF00067p450componentendoplasmic reticulum membranecomponentintracellular membrane-bounded organellefunctionaromatase activityfunctioncaffeine oxidase activityfunctiondemethylase activityfunctionelectron carrier activityfunctionenzyme bindingfunctionheme bindingfunctioniron ion bindingfunctionmonooxygenase activityfunctionoxidoreductase activityfunctionoxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenprocessalkaloid metabolic processprocessarachidonic acid metabolic processprocesscellular respirationprocesscellular response to cadmium ionprocessdibenzo-p-dioxin metabolic processprocessdrug catabolic processprocessdrug metabolic processprocessepoxygenase P450 pathwayprocessexogenous drug catabolic processprocessheterocycle metabolic processprocesshydrogen peroxide biosynthetic processprocesslung developmentprocessmethylationprocessmonocarboxylic acid metabolic processprocessmonoterpenoid metabolic processprocessomega-hydroxylase P450 pathwayprocessoxidation-reduction processprocessoxidative deethylationprocessoxidative demethylationprocessporphyrin-containing compound metabolic processprocesspost-embryonic developmentprocessregulation of gene expressionprocessresponse to estradiolprocessresponse to immobilization stressprocessresponse to lipopolysaccharideprocesssmall molecule metabolic processprocesssteroid catabolic processprocesstoxin biosynthetic processprocessxenobiotic metabolic processunknown

载体

运输工具

药物反应

效应

不良反应